Middle East Pemetrexed Market Analysis from 2022 to 2034 Containing Market Size, Share along with its CAGR, Forecast and Trends

Top Countries — Revenue

USD Million/Billion

Access the full forecast model.

Country-level data · Company profiles · Editable dataset · Analyst consultation included.

Middle East Pemetrexed Market Analysis — Presence

Geographical Analysis

Click countries to explore
Loading map…

Country Analysis

Middle East Pemetrexed Market Analysis 2026

Region / Country 2021 (A)2025 (A)2033 (P) CAGR
Middle East Pemetrexed Totalxxxxxxxxxxxx2.2%
Saudi Arabiaxxxxxxxxxxxxxxxx
Turkeyxxxxxxxxxxxx1.7%
UAExxxxxxxxxxxxxxxx
Egyptxxxxxxxxxxxx2.5%
Qatarxxxxxxxxxxxxxxxx
Rest of Middle Eastxxxxxxxxxxxx1.2%

A = Actual · E = Estimated · P = Projected · 🔒 Locked values require full access. Click headers to sort.

Unlock full regional dataset →

Segmentation Analysis

Strength breakdown · Illustrative 2025 shares shown free · Full-period forecast in paid report.

100mg Middle East Pemetrexed Market Analysis
XX
100mg Market Size 2025
XX %
CAGR
Locked · Full data in paid report
200mg Middle East Pemetrexed Market Analysis
XX
200mg Market Size 2025
XX %
CAGR
Locked · Full data in paid report

Market size by (Illustrative, 2025)
Share distribution (2025)

Disclaimer: The charts and graphs are for illustrative purposes only and do not represent actual market values. To access accurate quantitative data, please request a paid report or request free sample.

To learn more about market share and segmentation, request the free sample pages.

Competitor Analysis

Competitive Landscape of the Pemetrexed Market

The Pemetrexed Market features key players such as Eli Lilly and Company, Pfizer Inc., and Fresenius Kabi, among others. These companies compete in offering innovative formulations, expanding indications, and strategic partnerships to maintain their market share and meet the growing demand for advanced cancer treatments globally.

January 2023: Sun Pharma, an Indian pharmaceutical company, purchases Concert, a U.S.-based company, for $576 million. (Source: https://www.reuters.com/markets/deals/indias-sun-pharma-acquire-us-based-concert-576-mln-2023-01-19/ ) May 2022: Hengrui Pharma reports that in a global Phase 3 trial for advanced hepatocellular carcinoma, the combination of frontline Camrelizumab with Rivoceranib notably enhanced progression-free survival and overall survival. (Source: https://www.hengrui.com/en/media/detail-244.html )

Click any bar or cell to request the full company profile
Top Companies (In no particular order)2022 (A)2023 (A)2024 (A)2025 (A)
Company 1••• ••• ••• •••
Company 2••• ••• ••• •••
Company 3••• ••• ••• •••
Company 4••• ••• ••• •••
Company 5••• ••• ••• •••

We Provide Regional Breakdown of this Companies and Company specific to any Country, Region, Product/ service as well. We cover market share analysis for publicly listed companies as well as privately held companies, subject to data availability.

Request company profile for validation →

Report Scope & Analysis

According to Cognitive Market Research, the global Pemetrexed Market size was estimated at USD 2541.2 Million, out of which the Middle East and Africa held the major market of around 2% of the global revenue with a market size of USD 50.82 million in 2024 and will grow at a compound annual growth rate (CAGR) of 2.2 % from 2024 to 2031.

  • The GCC Countries Pemetrexed Market is projected to witness growth at a CAGR of 3.0 % during the forecast period, with a market size of USD 21.75 million in 2024. Pemetrexed sales flourished due to the Improved healthcare infrastructure and significant investments in oncology.
  • The Egypt Pemetrexed Market is projected to witness growth at a CAGR of 2.5 % during the forecast period, with a market size of USD 5.34 million in 2024.
  • The South Africa Pemetrexed Market is projected to witness growth at a CAGR of 3.2 % during the forecast period, with a market size of USD 8.03 million in 2024. Pemetrexed sales flourished in South Africa due to the enhancement of cancer care facilities and increasing awareness.
  • The Turkey Pemetrexed Market is projected to witness growth at a CAGR of 1.7 % during the forecast period, with a market size of USD 4.37 million in 2024.
  • The Nigeria Pemetrexed Market is projected to witness growth at a CAGR of 1.3 % during the forecast period, with a market size of USD 5.34 million in 2024.
  • The Rest of the MEA Pemetrexed Market is projected to witness growth at a CAGR of 1.2 % during the forecast period, with a market size of USD 6.00 million in 2024.

The Pemetrexed market in the Middle East and Africa is growing due to improving healthcare infrastructure and increasing investments in the pharmaceutical sector. Hospital pharmacies are predominant, as many cancer treatments are administered in hospital settings. Retail pharmacies are seeing growth due to expanding healthcare access and outpatient services. Online pharmacies are also beginning to gain popularity, offering convenience and improved medication access in regions with digital advancements.

 

Analyst Conclusion

Our study will explain complete manufacturing process along with major raw materials required to manufacture end-product. This report helps to make effective decisions determining product position and will assist you to understand opportunities and threats around the globe.

The Middle East Pemetrexed Market Analysis is witnessing significant growth in the near future.

In 2023, the 100mg segment accounted for a notable share of the Middle East Pemetrexed Market Analysis.

Supriya Yadav
Supriya Yadav Verified Analyst
Research Analyst
LinkedIn Profile Book a free Consultation

Frequently Asked Questions

Middle East Pemetrexed Market Analysis market size and growth rate is provided in the report covering 2021-2025 historical and 2025-2033 forecast data.
Major factors including drivers, restraints, opportunities and challenges are analyzed with detailed insights.
Top manufacturers and others are profiled in the report.
Segments include Strength, Distribution Channel and additional sub-segments.
Regional analysis covers all major markets. The report identifies the dominant region and provides country-level data.
Sample pages can be obtained on demand from the website. 24/7 chat support and direct call services are available.

★ Reviews

Rate this report

Middle East Pemetrexed Market Analysis — Table of Contents

Disclaimer:
  • This is just a redacted sample pages of the actual deliverable report and only for representative purposes
  • Charts/Graphs/Numbers/data are only for Representative purposes and do not depict actual statistics.
  • The table of Contents differs according to the user License selection. Current Displayed TOC is for the Corporate User License Report Edition. TOC Customization options: Add or Remove section/s Or chapter/s from the report.
  • Specific Tables, Graphs, Sections, and Chapters can be ordered at a discounted price.
  • If applicable; On Request Volume Data will also be provided (at an Additional Cost).
Report Scope
Strength100mg, 200mg
Distribution ChannelHospital Pharmacies, Retail Pharmacies, Online Pharmacies
End UserHospital Pharmacies, Pharmaceutical Companies
List of CompetitorsEli Lilly and Company (USA), Pfizer Inc. (USA), Fresenius Kabi (Germany), Teva Pharmaceutical Industries Ltd. (Israel), Accord Healthcare Limited (U.K.), Dr. Reddy's Laboratories Ltd. (India), Mylan N.V. (USA), Sun Pharmaceutical Industries Ltd. (India), Sandoz International GmbH (Germany), Jiangsu Hengrui Medicine Co., Ltd. (China)

  • Chapter 1. Competitor Analysis (Subject to Data Availability (Private Players))

    • 1.1 Top Competitors Analysis
      • 1.1.1 Top Players Ranking 2024
      • 1.1.2 New Product Launch Analysis
    • 1.2 Company Profile (Data Subject to Availability) Sample Format
      • 1.2.1 Eli Lilly and Company (USA)
        • 1.2.1.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
        • 1.2.1.2 Business Overview
        • 1.2.1.3 R&D Investment (Subject to data availability)
        • 1.2.1.4 Financials (Subject to data availability)
        • 1.2.1.5 Product Types Specification
        • 1.2.1.6 Business Strategy
        • 1.2.1.7 Recent Developments
        • 1.2.1.8 Management Change
        • 1.2.1.9 S.W.O.T Analysis
      • 1.2.2 Pfizer Inc. (USA)
        • 1.2.2.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
        • 1.2.2.2 Business Overview
        • 1.2.2.3 R&D Investment (Subject to data availability)
        • 1.2.2.4 Financials (Subject to data availability)
        • 1.2.2.5 Product Types Specification
        • 1.2.2.6 Business Strategy
        • 1.2.2.7 Recent Developments
        • 1.2.2.8 Management Change
        • 1.2.2.9 S.W.O.T Analysis
      • 1.2.3 Fresenius Kabi (Germany)
        • 1.2.3.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
        • 1.2.3.2 Business Overview
        • 1.2.3.3 R&D Investment (Subject to data availability)
        • 1.2.3.4 Financials (Subject to data availability)
        • 1.2.3.5 Product Types Specification
        • 1.2.3.6 Business Strategy
        • 1.2.3.7 Recent Developments
        • 1.2.3.8 Management Change
        • 1.2.3.9 S.W.O.T Analysis
      • 1.2.4 Teva Pharmaceutical Industries Ltd. (Israel)
        • 1.2.4.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
        • 1.2.4.2 Business Overview
        • 1.2.4.3 R&D Investment (Subject to data availability)
        • 1.2.4.4 Financials (Subject to data availability)
        • 1.2.4.5 Product Types Specification
        • 1.2.4.6 Business Strategy
        • 1.2.4.7 Recent Developments
        • 1.2.4.8 Management Change
        • 1.2.4.9 S.W.O.T Analysis
      • 1.2.5 Accord Healthcare Limited (U.K.)
        • 1.2.5.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
        • 1.2.5.2 Business Overview
        • 1.2.5.3 R&D Investment (Subject to data availability)
        • 1.2.5.4 Financials (Subject to data availability)
        • 1.2.5.5 Product Types Specification
        • 1.2.5.6 Business Strategy
        • 1.2.5.7 Recent Developments
        • 1.2.5.8 Management Change
        • 1.2.5.9 S.W.O.T Analysis
      • 1.2.6 Dr. Reddy's Laboratories Ltd. (India)
        • 1.2.6.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
        • 1.2.6.2 Business Overview
        • 1.2.6.3 R&D Investment (Subject to data availability)
        • 1.2.6.4 Financials (Subject to data availability)
        • 1.2.6.5 Product Types Specification
        • 1.2.6.6 Business Strategy
        • 1.2.6.7 Recent Developments
        • 1.2.6.8 Management Change
        • 1.2.6.9 S.W.O.T Analysis
      • 1.2.7 Mylan N.V. (USA)
        • 1.2.7.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
        • 1.2.7.2 Business Overview
        • 1.2.7.3 R&D Investment (Subject to data availability)
        • 1.2.7.4 Financials (Subject to data availability)
        • 1.2.7.5 Product Types Specification
        • 1.2.7.6 Business Strategy
        • 1.2.7.7 Recent Developments
        • 1.2.7.8 Management Change
        • 1.2.7.9 S.W.O.T Analysis
      • 1.2.8 Sun Pharmaceutical Industries Ltd. (India)
        • 1.2.8.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
        • 1.2.8.2 Business Overview
        • 1.2.8.3 R&D Investment (Subject to data availability)
        • 1.2.8.4 Financials (Subject to data availability)
        • 1.2.8.5 Product Types Specification
        • 1.2.8.6 Business Strategy
        • 1.2.8.7 Recent Developments
        • 1.2.8.8 Management Change
        • 1.2.8.9 S.W.O.T Analysis
      • 1.2.9 Sandoz International GmbH (Germany)
        • 1.2.9.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
        • 1.2.9.2 Business Overview
        • 1.2.9.3 R&D Investment (Subject to data availability)
        • 1.2.9.4 Financials (Subject to data availability)
        • 1.2.9.5 Product Types Specification
        • 1.2.9.6 Business Strategy
        • 1.2.9.7 Recent Developments
        • 1.2.9.8 Management Change
        • 1.2.9.9 S.W.O.T Analysis
      • 1.2.10 Jiangsu Hengrui Medicine Co.
        • 1.2.10.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
        • 1.2.10.2 Business Overview
        • 1.2.10.3 R&D Investment (Subject to data availability)
        • 1.2.10.4 Financials (Subject to data availability)
        • 1.2.10.5 Product Types Specification
        • 1.2.10.6 Business Strategy
        • 1.2.10.7 Recent Developments
        • 1.2.10.8 Management Change
        • 1.2.10.9 S.W.O.T Analysis
      • 1.2.11 Ltd. (China)
        • 1.2.11.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
        • 1.2.11.2 Business Overview
        • 1.2.11.3 R&D Investment (Subject to data availability)
        • 1.2.11.4 Financials (Subject to data availability)
        • 1.2.11.5 Product Types Specification
        • 1.2.11.6 Business Strategy
        • 1.2.11.7 Recent Developments
        • 1.2.11.8 Management Change
        • 1.2.11.9 S.W.O.T Analysis

  • Chapter 2. Global Pemetrexed Market Analysis

    • 2.1 Global Pemetrexed Market Analysis
    • 2.2 Global Pemetrexed Market Analysis by Strength
    • 2.3 Global Pemetrexed Market Analysis by Distribution Channel
    • 2.4 Global Pemetrexed Market Analysis by End User

  • Chapter 3. Middle East Pemetrexed Market Analysis

    • 3.1 Middle East Pemetrexed Market Analysis
    • 3.2 Middle East Pemetrexed Market Analysis by Country
    • 3.3 Middle East Pemetrexed Market Analysis by Strength
    • 3.4 Middle East Pemetrexed Market Analysis by Distribution Channel
    • 3.5 Middle East Pemetrexed Market Analysis by End User
    • 3.6 Middle East Pemetrexed Market Analysis by Key Players

  • Chapter 4. Saudi Arabia Pemetrexed Market Analysis

    • 4.1 Saudi Arabia Pemetrexed Market Analysis
    • 4.2 Saudi Arabia Pemetrexed Market Analysis by Strength
    • 4.3 Saudi Arabia Pemetrexed Market Analysis by Distribution Channel
    • 4.4 Saudi Arabia Pemetrexed Market Analysis by End User
    • 4.5 Saudi Arabia Pemetrexed Market Analysis by Key Players

  • Chapter 5. Turkey Pemetrexed Market Analysis

    • 5.1 Turkey Pemetrexed Market Analysis
    • 5.2 Turkey Pemetrexed Market Analysis by Strength
    • 5.3 Turkey Pemetrexed Market Analysis by Distribution Channel
    • 5.4 Turkey Pemetrexed Market Analysis by End User
    • 5.5 Turkey Pemetrexed Market Analysis by Key Players

  • Chapter 6. UAE Pemetrexed Market Analysis

    • 6.1 UAE Pemetrexed Market Analysis
    • 6.2 UAE Pemetrexed Market Analysis by Strength
    • 6.3 UAE Pemetrexed Market Analysis by Distribution Channel
    • 6.4 UAE Pemetrexed Market Analysis by End User
    • 6.5 UAE Pemetrexed Market Analysis by Key Players

  • Chapter 7. Egypt Pemetrexed Market Analysis

    • 7.1 Egypt Pemetrexed Market Analysis
    • 7.2 Egypt Pemetrexed Market Analysis by Strength
    • 7.3 Egypt Pemetrexed Market Analysis by Distribution Channel
    • 7.4 Egypt Pemetrexed Market Analysis by End User
    • 7.5 Egypt Pemetrexed Market Analysis by Key Players

  • Chapter 8. Qatar Pemetrexed Market Analysis

    • 8.1 Qatar Pemetrexed Market Analysis
    • 8.2 Qatar Pemetrexed Market Analysis by Strength
    • 8.3 Qatar Pemetrexed Market Analysis by Distribution Channel
    • 8.4 Qatar Pemetrexed Market Analysis by End User
    • 8.5 Qatar Pemetrexed Market Analysis by Key Players

  • Chapter 9. Rest of Middle East Pemetrexed Market Analysis

    • 9.1 Rest of Middle East Pemetrexed Market Analysis
    • 9.2 Rest of Middle East Pemetrexed Market Analysis by Strength
    • 9.3 Rest of Middle East Pemetrexed Market Analysis by Distribution Channel
    • 9.4 Rest of Middle East Pemetrexed Market Analysis by End User
    • 9.5 Rest of Middle East Pemetrexed Market Analysis by Key Players

  • Chapter 10. Strength Analysis

    • 10.1 100mg
    • 10.2 200mg

  • Chapter 11. Distribution Channel Analysis

    • 11.1 Hospital Pharmacies
    • 11.2 Retail Pharmacies
    • 11.3 Online Pharmacies

  • Chapter 12. End User Analysis

    • 12.1 Hospital Pharmacies
    • 12.2 Pharmaceutical Companies

  • Chapter 13. Qualitative Analysis (Subject to Data Availability)

    • 13.1 Market Drivers
    • 13.2 Market Restraints
    • 13.3 Market Trends
    • 13.4 Market Opportunity
    • 13.5 Technological Road Map (Subject to Data Availability)
    • 13.6 Product Life Cycle (Subject to Data Availability)
    • 13.7 Customer and Buyer Behavior Analysis
      • 13.7.1 Digital Engagement, Customer Experience & Relationship Analysis
      • 13.7.2 Customer Buying Behavior & Purchase Decision Analysis
      • 13.7.3 Vendor Selection, Supplier Preferences & Future Demand Trends
      • 13.7.4 Pricing, Affordability & Value Perception Analysis
      • 13.7.5 Customer Segmentation & Demand Pattern Analysis
    • 13.8 Industrial Chain Analysis (Subject to Data Availability)
      • 13.8.1 Industry Chain Analysis
      • 13.8.2 Manufacturing Cost Analysis
      • 13.8.3 Supply Side Analysis
        • 13.8.3.1 Raw Material Analysis
        • 13.8.3.2 Raw Material Procurement Analysis
        • 13.8.3.3 Raw Material Price Trend Analysis
    • 13.9 PESTEL Analysis
      • 13.9.1 Environmental Factors
      • 13.9.2 Legal Factors
      • 13.9.3 Technological Factors
      • 13.9.4 Economic Factors
      • 13.9.5 Political Factors
      • 13.9.6 Social Factors
    • 13.10 Porter’s Five Forces Analysis
      • 13.10.1 Degree of Competition
      • 13.10.2 Threat of Substitutes
      • 13.10.3 Threat of New Entrants
      • 13.10.4 Bargaining Power of Buyers
      • 13.10.5 Bargaining Power of Suppliers
    • 13.11 Patent Analysis (Subject to Data Availability)
    • 13.12 ESG Analysis
    • 13.13 Geopolitical Outlook
      • 13.13.1 Global Power Realignment & Strategic Alliances
      • 13.13.2 Geopolitical Risk Landscape & Conflict Hotspots
      • 13.13.3 International Trade Relations & Market Access Environment
      • 13.13.4 Regulatory & Policy Shifts Impacting Cross-Border Operations
      • 13.13.5 Supply Chain Resilience, Localization & Resource Nationalism
      • 13.13.6 Technology Sovereignty & Digital Geopolitics
      • 13.13.7 Strategic Implications for Investment, Growth & Market Entry
    • 13.14 AI & Market Transformation
      • 13.14.1 Competitive Landscape Disruption & Strategic Shifts
      • 13.14.2 AI-Driven Transformation of Industry Value Chain
      • 13.14.3 Evolution of Business Models & Revenue Streams
      • 13.14.4 AI-Driven Product, Service & Innovation Transformation
      • 13.14.5 Customer Behavior, AI Adoption & Future Market Evolution

  • Chapter 14. Research Findings

    • 14.1 Key Takeaways
    • 14.2 Analyst Point of View
    • 14.3 Assumptions and Acronyms

  • Chapter 15. Research Methodology and Sources

    • 15.1 Primary Data Collection
      • 15.1.1 Steps for Primary Data Collection
        • 15.1.1.1 Identification of KOL
      • 15.1.2 Backward Integration
      • 15.1.3 Forward Integration
      • 15.1.4 How Primary Research Help Us
      • 15.1.5 Modes of Primary Research
    • 15.2 Secondary Research
      • 15.2.1 How Secondary Research Help Us
      • 15.2.2 Sources of Secondary Research
    • 15.3 Data Validation
      • 15.3.1 Data Triangulation
    • 15.4 Data Representation

Athenaeum AI Dashboard

Research Framework · 70:30 Primary:Secondary

Our Proprietary Methodology

Cognitive Market Research and Consulting "The Full Truth" methodology — a rigorous triangulation process that combines primary research, secondary validation, and expert calibration. Implemented by Supriya Yadav and team for the Middle East Pemetrexed Market Analysis Market analysis.

01

Primary Intelligence Gathering

Direct interviews with 50+ industry stakeholders including manufacturers, distributors, end-users, and regulatory bodies across all six regions.

02

Secondary Data Triangulation

Cross-referencing against trade databases, customs records, financial filings, patent databases, and verified industry publications.

03

Expert Validation Protocol

Each data point undergoes validation by minimum two independent domain experts with 15+ years of industry experience.

04

Athenaeum AI Processing

Our proprietary AI platform aggregates, normalizes, and identifies patterns across 10,000+ data points to surface non-obvious insights.

05

Editorial & QA Review

Final review by senior analysts ensures accuracy, coherence, and actionability of all insights and recommendations.

Data Assurance Metrics
Data Points Validated 10,400+
Expert Interviews 54
Countries Covered 39+
Company Profiles 22+
Forecast Accuracy (Historical) 94.2%
Analytical Coverage
Market Sizing Revenue Forecast CAGR Analysis Competitor Benchmarking SWOT Porter's Analysis PESTEL Value Chain ESG Analysis Tariff Impact Patent Mapping Tech Trends

To maintain the integrity of our proprietary methodology and protect our elite expert network, specific source disclosures are reserved for full-access partners. Our research framework is anchored by a 70:30 primary-to-secondary ratio, ensuring your strategy is driven by real-time market intelligence rather than recycled, publicly available, or AI-generated data. Every deliverable includes an exhaustive source directory and grants direct analyst access.

Sources from the Pharma and Healthcare Industry

How We Serve You

The Three Pillars of End-to-End Market Research Services

We don't just hand over data. We partner with your team across three integrated service lines — each designed to give you decision-grade intelligence on the Middle East Pemetrexed Market Analysis market.

Service 01

Market Survey

B2B B2C

Structured primary research across both B2B and B2C channels. We design and execute custom surveys targeting manufacturers, distributors, procurement heads, and end-consumers in the middle east pemetrexed market analysis ecosystem — validated by our global panel of 10,000+ industrial respondents.

What's Included
  • Buyer intent & sentiment analysis
  • Purchase cycle mapping
  • Price sensitivity research
  • Channel preference profiling
  • Competitive perception study
Most Requested
Service 02

Customized Market Data & Reports

Custom Ready Report

Choose from our ready-to-access 8th Edition report or commission a fully customized dataset tailored to your exact strategic questions. Cross-splits, custom geographies, proprietary segmentation — we build the intelligence asset your board actually needs.

What's Included
  • Ready syndicate report
  • Custom data scope & segmentation
  • Excel quantitative models
  • Board-ready PPT with key findings
  • Secure cloud portal access
Service 03

Strategic Consultation

With Survey With Report

Every survey and every report comes with dedicated analyst consultation. Our senior research team walks your leadership through findings, answers strategic questions in real-time, and helps translate data into your next board presentation or investment thesis.

What's Included
  • Dedicated analyst assigned to you
  • Live walkthrough of findings
  • Strategic Q&A sessions
  • Go-to-market recommendations
  • NDA-protected engagement

Customize This Report

Tell us the specific segments, regions, or companies you need — and we will tailor the deliverable to your requirements.